Acute Bacterial Skin and Skin Structure Infections Market to Grow Substantially by 2032, Assesses DelveInsight | Key Companies - Melinta, AbbVie, Basilea, Motif Bio, Cubist, Paratek, Durata, The Medicine Company
23. August 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Acute Bacterial Skin and Skin Structure Infections Market to Grow Substantially by 2032, Assesses DelveInsight | Key Companies - Melinta, AbbVie,...
Acute Bacterial Skin and Skin Structure Infections Pipeline Featuring Plethora of Emerging Drugs, Key Companies
24. Mai 2021 20:30 ET
|
DelveInsight Business Research LLP
Los Angeles, USA, May 24, 2021 (GLOBE NEWSWIRE) -- Acute Bacterial Skin and Skin Structure Infections Pipeline Featuring Plethora of Emerging Drugs, Key Companies Ceftobiprole Medocaril under...
Melinta Therapeutics Partner, Menarini Group, Submits Marketing Authorization Application for Delafloxacin in Europe
08. März 2018 07:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., March 08, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
Melinta Therapeutics’ Commercial Partner Eurofarma Laboratórios Submits Marketing Authorization Application for Delafloxacin in Argentina
20. Februar 2018 07:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
Melinta Therapeutics Launches Antibiotic Baxdela™ (delafloxacin) in the United States
29. Januar 2018 07:00 ET
|
Melinta Therapeutics
– Approved for adult patients with acute bacterial skin and skin structure infections (ABSSSI) – – Provides coverage of gram-positive and gram-negative pathogens; only FDA-approved fluoroquinolone...
Melinta Therapeutics Announces FDA Clearance of Antimicrobial Susceptibility Tests Concurrent with Baxdela Launch in the United States
30. Oktober 2017 08:01 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing and commercializing novel antibiotics to treat serious bacterial infections, announced...
Melinta Therapeutics Presents Outcomes of Baxdela Treatment of Gram-Positive and Gram-Negative Pathogens at IDWeek
04. Oktober 2017 13:13 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., Oct. 04, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
Melinta Therapeutics Announces U.S. FDA Approval of Baxdela™ (Delafloxacin) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
19. Juni 2017 16:30 ET
|
Melinta Therapeutics
- Baxdela offers a new option for treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) including hospital-treated skin infections in oral and IV formulations as...
Cempra Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results
28. Februar 2017 06:45 ET
|
Cempra, Inc.
—Management to host webcast and conference call today at 8:45 a.m. ET— CHAPEL HILL, N.C., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company...
Cempra’s Fusidic Acid Achieves Primary Endpoint in Phase 3 Study of ABSSSI
24. Februar 2017 07:00 ET
|
Cempra, Inc.
—Fusidic acid met primary endpoint and secondary efficacy endpoints— —Fusidic acid well tolerated in the study— CHAPEL HILL, N.C., Feb. 24, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a...